Cardiovascular Risk FactorsNCT00848380
Management of Cardiovascular Risk Factors
An observational study of Cardiovascular Risk Factors and Cardiovascular Diseases, run by AstraZeneca at 36 sites in Switzerland.
Trial summary
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Risk Factors, Cardiovascular Diseases
- How many people
- 1,492 participants
- Where
- 36 sitesSwitzerland
- Study dates
- Feb 2009to Dec 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients with hypertension and hyperlipidemia and other CV risk factors
Who may be able to join
- Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
- Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
- Patients received during the observation time new cholesterol lowering and hypertension treatment
Who cannot join
- Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment
Trial locations and contacts
36 sites in 1 country.
36 sites in 1 country
Switzerland36 sites
Research Site
Affoltern am Albis, Canton of Zurich
Research Site
Andeer, Kanton Graubünden
Research Site
Arbedo, Canton Ticino
Research Site
Bassins, Canton of Vaud
Research Site
Bellinzona, Canton Ticino
Research Site
Claro, Canton Ticino
Research Site
Coldrerio, Canton Ticino
Research Site
Feldmeilen, Canton of Zurich
Research Site
Frick, Canton of Aargau
Research Site
Geneva, Canton of Geneva
Research Site
Gerlafingen, Canton of Solothurn
Research Site
Gland, Canton of Vaud
Research Site
Herrliberg, Canton of Zurich
Research Site
Ilanz, Kanton Graubünden
Research Site
Langnau am Albis, Canton of Zurich
Research Site
Lausanne, Canton of Vaud
Research Site
Le Lignon, Canton of Geneva
Research Site
Locarno, Canton Ticino
Research Site
Lohn SO, Canton of Solothurn
Research Site
Lugano, Canton Ticino
Research Site
Meyrin, Canton of Geneva
Research Site
Montreux, Canton of Vaud
Research Site
Muralto, Canton Ticino
Research Site
Neuenhof, Canton of Aargau
Research Site
Nyon, Canton of Vaud
Research Site
Richterswil, Canton of Zurich
Research Site
Riehen, Canton of Basel-City
Research Site
Rorschach, Canton of St. Gallen
Research Site
Rüti, Canton of Zurich
Research Site
Sankt Gallen, Canton of St. Gallen
Research Site
Schwyz, Canton of Schwyz
Research Site
Thun, Canton of Bern
Research Site
Wynigen, Canton of Bern
Research Site
Zuchwil, Canton of Solothurn
Research Site
Zug, Canton of Zug
Research Site
Zurich, Canton of Zurich
About this study
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia
- Keywords
- Hypertension, hyperlipidemia
- Medical subject headings
- Cardiovascular Diseases, Hypertension, Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients with hypertension and hyperlipidemia and other CV risk factors |
What is being measured
The primary outcome is the main question the study is designed to answer.
The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia.
Measured: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2009 (estimated)
- Study startFeb 2009
- Primary completionDec 2009
- Study completionDec 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular Risk FactorsStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 1,492 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00848380
- Sponsor's protocol ID
- NIS-CCH-DUM-2008/2
- Status last verified
- Nov 2010
- First submitted
- 19 Feb 2009
- Last updated
- 16 Nov 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Nov 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Management of Cardiovascular Risk Factors
- ClinicalTrials.gov ID
- NCT00848380
- Acronym / sponsor ID
- NIS-CCH-DUM-2008/2
- Keywords
- Hypertension, hyperlipidemia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,492 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Feb 2009
- Primary completion
- Dec 2009 (actual)
- Study completion
- Dec 2009 (actual)
- First posted
- 20 Feb 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Patients with hypertension and hyperlipidemia and other CV risk factors |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with hypertension and hyperlipidemia and other CV risk factors
Key inclusion criteria (3 listed)
- Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
- Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
- Patients received during the observation time new cholesterol lowering and hypertension treatment
Key exclusion criteria (1 listed)
- Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia.
Time frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Nov 2010.
Related trials for Cardiovascular Risk Factors
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Not yet recruiting
Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk
Hypertension, Hyperglycemia
Recruiting
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)
Heart Failure, Cardiovascular Risk Factors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
36 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Risk Factors and Cardiovascular Diseases, run by AstraZeneca at 36 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. (time frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Nov 2010.